ASCO® 2024 Insights: "Ultra-Sensitive ctDNA Mutation Tracking to Identify MRD and Predict Relapse in Patients With Early BC"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Ultra-Sensitive ctDNA Mutation Tracking to Identify MRD and Predict Relapse in Patients With Early BC"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Isaac Garcia-Murillas

672 views

June 17, 2024

0 Comments

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Feat. J. O’Shaughnessy

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri

2024 ASCO® Annual Meeting Insights Hub: Breast Videos

24:36

2024 ASCO® Annual Meeting Insights Hub

ASCO 2024 Highlights: Insights From Key Abstracts on mBC

Feat. S. Aithal

09:34

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Impact of ctDNA Surveillance on Clinical …

Feat. M. Lipsyc-Sharf

05:06

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Genomic Alterations in HR+/HER2- Metastat…

Feat. M. Bhave

View All

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

Feat. R. O'Regan

14:16

Dana-Farber Cancer Institute

Year in Review: Breast Cancer

Feat. P. Tarantino

09:55

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future H…

Feat. E. Hamilton

17:39

Yale School of Medicine

2023 Menopause Update

Feat. M. Minkin

10:53

Kirollos Hanna

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

28:36

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "eBC Expert Panel Discussion on Key Trials …

Feat. H. Rugo, K. Jhaveri

09:19

Insights from 2023 SABCS

SABCS 2023 Insights: "Biology or Stage? Tailoring Treatment for…

Feat. K. Kalinsky

05:43

Total Health

Neoadjuvant Chemo for HR+ BC: Year in Review

Feat. C. Ma

57:44

Vogl, NY

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl

17:50

AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde

27:01

Scripps Health

CDK4/6 Inhibitor Therapy in Early-Stage HR+/HER2- BC

Feat. S. Sammons

22:34

Dana-Farber Cancer Institute

What's New in Breast Cancer?

Feat. S. Tolaney

10:34

Sara Tolaney

ASCO® 2024 Noteworthy Abstracts in Breast Cancer

Feat. H. Rugo

36:18

Insights from ESMO Breast 2024 Annual Meeting

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…

Feat. H. Rugo

27:04

Fengting Yan

Cancer Screening Molecular Tools

16:19

Wassim Mchayleh

Optimizing Adjuvant Treatment in High-Risk HR+/HER2- eBC: Patient Se…

10:27

Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Role for CDK 4/6i in the Adjuv…

Feat. S. Tolaney, H. Rugo

13:49

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "NATALEE Trial - Baseline Characteristics …

Feat. D. Yardley

12:07

Sara Tolaney

ESMO 2024 Noteworthy Abstracts in Breast Cancer

Feat. H. Rugo

15:19

Alberto Zambelli

Login

Login

Join VuMedi

ASCO® 2024 Insights: "Ultra-Sensitive ctDNA Mutation Tracking to Identify MRD and Predict Relapse in Patients With Early BC"

2024 ASCO® Annual Meeting Insights Hub: Breast Videos

Related Content